Victory Square Technologies Inc (TSE:VST) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Victory Square Technologies Inc. expands its medical offerings through Hydreight Technologies with the addition of Tirzepatide, enhancing their weight loss portfolio that already includes GLP-1 injections. This move aims to provide cost-effective diabetes and weight loss treatments across the US, leveraging a robust network of over 3,000 nurses and 107 white-label locations. Tirzepatide, an FDA-approved medicine for type 2 diabetes, is recognized for its weight loss benefits and will now be available in over 700 cities nationwide.
For further insights into TSE:VST stock, check out TipRanks’ Stock Analysis page.
